Related Experiment Video
Updated: Mar 13, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
The rationale for targeting nectin-4 in pancreatic cancer
Sarah Cronjaeger1, Lena Seifert2, Adrian M Seifert3
1Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
None:
Nectin-4 is an immunoglobulinlike cell adhesion molecule that contributes to tumor aggressiveness and immune evasion in pancreatic ductal adenocarcinoma (PDAC). Its high and selective expression on pancreatic cancer cells, together with the clinical efficacy of nectin-4-targeted antibody-drug conjugates in other solid tumors, establishes nectin-4 as a compelling therapeutic target in PDAC.

